References
- Pui C H, Evans W E. Acute lymphoblastic leukemia. N Eng J Med 1998; 339: 605–615
- Levi F, Lucchini F, Negri E, Barbui T, La Vecchia C. Trends in mortality from leukemia in subsequent age groups. Leukemia 2000; 14: 1980–1985
- Szocinski J L, Khaled A R, Hixon J, Halverson D, Funakoshi S, Fanslow W C, et al. Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax. Blood 2002; 100: 217–223
- Schattner E J, Elkon K B, Yoo D H, Tumang J, Krammer P H, Crow M K, et al. CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med 1995; 182: 1557–1565
- Kelley S K, Gelzleichter T, Xie D, Lee W P, Darbonne W C, Qureshi F, et al. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol 2006; 148: 1116–1123
- Law C L, Gordon K A, Collier J, Klussman K, McEarchern J A, Cerveny C G, et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005; 65: 8331–8338
- Longley D B, Harkin D P, Johnston P G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330–338
- D'Costa S, Hurwitz J L. Customized mitogen or antibody treatments enhance the sensitivity of lymphoid tumors to 5-fluorouracil in vitro and in vivo. Leuk Lymphoma 2003; 44: 841–847
- Hill S C, Youde S J, Man S, Teale G R, Baxendale A J, Hislop A, et al. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol 2005; 174: 41–50
- Ghia P, Boussiotis V A, Schultze J L, Cardoso A A, Dorfman D M, Gribben J G, et al. Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood 1998; 91: 244–251
- D'Costa S S, Hurwitz J L. Phytohemagglutinin inhibits lymphoid tumor growth in vitro and in vivo. Leuk Lymphoma 2003; 44: 1785–1791
- Kotzin B L, Leung D Y, Kappler J, Marrack P. Superantigens and their potential role in human disease. Adv Immunol 1993; 54: 99–166
- Suffredini A F, Fromm R E, Parker M M, Brenner M, Kovacs J A, Wesley R A, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Eng J Med 1989; 321: 280–287
- Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265–4274
- Spina M, Tirelli U. Rituximab for HIV-associated lymphoma: weighing the benefits and risks. Curr Opin Oncol 2005; 17: 462–465